Mycophenolate mofetil in pediatric renal transplantation: a single center experience.

Hdl Handle:
http://hdl.handle.net/10147/207121
Title:
Mycophenolate mofetil in pediatric renal transplantation: a single center experience.
Authors:
Raheem, Omer A; Kamel, Mohamed H; Daly, Padraiq J; Mohan, Ponnusamy; Little, Dilly M; Awan, Atif; Hickey, David P
Affiliation:
Department of Urology, Beaumont Hospital, Beaumont, Ireland.
Citation:
Pediatr Transplant. 2011 May;15(3):240-4. doi: 10.1111/j.1399-3046.2009.01179.x.
Journal:
Pediatric transplantation
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207121
DOI:
10.1111/j.1399-3046.2009.01179.x
PubMed ID:
21492350
Abstract:
We assessed our long-term experience with regards to the safety and efficacy of MMF in our pediatric renal transplant population and compared it retrospectively to our previous non-MMF immunosuppressive regimen. Forty-seven pediatric renal transplants received MMF as part of their immunosuppressive protocol in the period from January 1997 till October 2006 (MMF group). A previously reported non-MMF group of 59 pediatric renal transplants was included for comparative analysis (non-MMF group). The MMF group comprised 29 boys and 18 girls, whereas the non-MMF group comprised 34 boys and 25 girls. Mean age was 11.7 and 12 yr in the MMF and non-MMF groups, respectively. The incidence of acute rejection episodes was 11 (23.4%) and 14 (24%) in the MMF and non-MMF group, respectively. Two (3.3%) grafts were lost in the non-MMF group compared with one (2.1%) in the MMF group. Twenty-one (44.68%) patients in the MMF group developed post-transplant infections compared with 12 (20.33%) in the non-MMF group (p < 0.0001). In conclusion, the use of MMF in pediatric renal transplantation was not associated with a lower rejection rate or immunological graft loss. It did, however, result in a significantly higher rate of viral infections.
Language:
eng
MeSH:
Adolescent; Child; Child, Preschool; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents/*therapeutic use; Infant; Kidney Transplantation/*methods; Male; Mycophenolic Acid/*analogs & derivatives/therapeutic use; Postoperative Complications; Retrospective Studies; Treatment Outcome
ISSN:
1399-3046 (Electronic); 1397-3142 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorRaheem, Omer Aen_GB
dc.contributor.authorKamel, Mohamed Hen_GB
dc.contributor.authorDaly, Padraiq Jen_GB
dc.contributor.authorMohan, Ponnusamyen_GB
dc.contributor.authorLittle, Dilly Men_GB
dc.contributor.authorAwan, Atifen_GB
dc.contributor.authorHickey, David Pen_GB
dc.date.accessioned2012-02-01T09:59:44Z-
dc.date.available2012-02-01T09:59:44Z-
dc.date.issued2012-02-01T09:59:44Z-
dc.identifier.citationPediatr Transplant. 2011 May;15(3):240-4. doi: 10.1111/j.1399-3046.2009.01179.x.en_GB
dc.identifier.issn1399-3046 (Electronic)en_GB
dc.identifier.issn1397-3142 (Linking)en_GB
dc.identifier.pmid21492350en_GB
dc.identifier.doi10.1111/j.1399-3046.2009.01179.xen_GB
dc.identifier.urihttp://hdl.handle.net/10147/207121-
dc.description.abstractWe assessed our long-term experience with regards to the safety and efficacy of MMF in our pediatric renal transplant population and compared it retrospectively to our previous non-MMF immunosuppressive regimen. Forty-seven pediatric renal transplants received MMF as part of their immunosuppressive protocol in the period from January 1997 till October 2006 (MMF group). A previously reported non-MMF group of 59 pediatric renal transplants was included for comparative analysis (non-MMF group). The MMF group comprised 29 boys and 18 girls, whereas the non-MMF group comprised 34 boys and 25 girls. Mean age was 11.7 and 12 yr in the MMF and non-MMF groups, respectively. The incidence of acute rejection episodes was 11 (23.4%) and 14 (24%) in the MMF and non-MMF group, respectively. Two (3.3%) grafts were lost in the non-MMF group compared with one (2.1%) in the MMF group. Twenty-one (44.68%) patients in the MMF group developed post-transplant infections compared with 12 (20.33%) in the non-MMF group (p < 0.0001). In conclusion, the use of MMF in pediatric renal transplantation was not associated with a lower rejection rate or immunological graft loss. It did, however, result in a significantly higher rate of viral infections.en_GB
dc.language.isoengen_GB
dc.subject.meshAdolescenten_GB
dc.subject.meshChilden_GB
dc.subject.meshChild, Preschoolen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshGraft Rejectionen_GB
dc.subject.meshGraft Survivalen_GB
dc.subject.meshHumansen_GB
dc.subject.meshImmunosuppressive Agents/*therapeutic useen_GB
dc.subject.meshInfanten_GB
dc.subject.meshKidney Transplantation/*methodsen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMycophenolic Acid/*analogs & derivatives/therapeutic useen_GB
dc.subject.meshPostoperative Complicationsen_GB
dc.subject.meshRetrospective Studiesen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.titleMycophenolate mofetil in pediatric renal transplantation: a single center experience.en_GB
dc.contributor.departmentDepartment of Urology, Beaumont Hospital, Beaumont, Ireland.en_GB
dc.identifier.journalPediatric transplantationen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.